Pfizer Inc. (NYSE:PFE) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 33.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,984,150 shares of the biopharmaceutical company’s stock after buying an additional 3,265,276 shares during the quarter. Van ECK Associates Corp’s holdings in Pfizer were worth $373,813,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. MCF Advisors LLC raised its position in shares of Pfizer by 3.7% during the 3rd quarter. MCF Advisors LLC now owns 27,590 shares of the biopharmaceutical company’s stock valued at $915,000 after buying an additional 975 shares during the period. U.S. Capital Wealth Advisors LLC increased its stake in Pfizer by 18.5% during the third quarter. U.S. Capital Wealth Advisors LLC now owns 503,170 shares of the biopharmaceutical company’s stock worth $16,690,000 after acquiring an additional 78,421 shares during the last quarter. Trust Co. of Toledo NA OH raised its position in Pfizer by 2.1% in the third quarter. Trust Co. of Toledo NA OH now owns 122,829 shares of the biopharmaceutical company’s stock valued at $4,074,000 after purchasing an additional 2,567 shares during the period. JGP Wealth Management LLC lifted its stake in shares of Pfizer by 3.4% in the 3rd quarter. JGP Wealth Management LLC now owns 60,487 shares of the biopharmaceutical company’s stock valued at $2,006,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Blossom Wealth Management grew its holdings in shares of Pfizer by 11.5% during the 3rd quarter. Blossom Wealth Management now owns 10,943 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 1,130 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $36.33.

Pfizer Stock Up 1.0 %

NYSE PFE traded up $0.25 during trading hours on Monday, hitting $25.65. 41,630,566 shares of the company were exchanged, compared to its average volume of 41,999,020. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market cap of $145.24 billion, a price-to-earnings ratio of 71.03, a PEG ratio of 1.14 and a beta of 0.61. The company has a 50 day moving average of $26.96 and a two-hundred day moving average of $28.36. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is currently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.